Yasemin Gündoğdu

Yasemin Gündoğdu

Auto-generated profile, based on publicly available information

Yasemin Gündoğdu

School of Medicine, Department of Internal Medicine Acıbadem Mehmet Ali Aydınlar University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in The Lancet Global Health
Verified
Journal Article
Open access
CSCatherine A Shaw
Catherine A Shaw
RPRiinu Pius
Riinu Pius
TDThomas M Drake
Thomas M Drake
LNLisa Norman
Lisa Norman
AAAdesoji O Ademuyiwa
Adesoji O Ademuyiwa
JLJean Wilguens Lartigue
Jean Wilguens Lartigue
Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide. A multimethods analysis was performed as part of the GlobalSurg 3 study—a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital. Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3·85 [95% CI 2·58–5·75]; p<0·0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63·0% vs 82·7%; OR 0·35 [0·23–0·53]; p<0·0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer. Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised. National Institute for Health and Care Research.

24 September 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
AUAnt Uzay
Ant Uzay
YGYasemin Gündoğdu
Yasemin Gündoğdu
BKBarış Koşan
Barış Koşan
TYTuğba Yetiş
Tuğba Yetiş
HGHatun Gür
Hatun Gür
SKS. Sami Kartı
S. Sami Kartı

18 November 2021 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
YGYasemin Gündoğdu
Yasemin Gündoğdu
ODOrhan Cem Deniz
Orhan Cem Deniz
DSDidem Saka
Didem Saka
GŞGürhan Şişman
Gürhan Şişman
SESibel Erdamar
Sibel Erdamar
IKİfTihar Köksal
İfTihar Köksal
Introduction: Sunitinib is a tyrosine kinase inhibitor that binds to vascular endothelial factor receptor currently used for the treatment of renal cell carcinoma, as well as for several other conditions such as gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. We present a patient with invasive diarrhea who was treated with sunitinib for metastatic renal cell carcinoma. Case report: Drug induced colitis was confirmed with colonoscopy from histopathological specimens. Clinical recovery of diarrhea was achieved with oral budesonide. Remarkably, the pathologic findings were observed in both the macroscopically normal mucosa and the mucosa with aphthous ulcers in the colon. Management & outcome: The patient was treated for sunitinib associated diarrhea, after exclusion of the other reasons. Metronidazole and piperacillin/tazobactam treatment were prescribed. Discussion: Diarrhea is a frequent symptom in patients treated with tyrosine kinase inhibitors, however the described pathologic findings have rarely been reported. Our aim is to emphasize the importance of close follow-up in patients treated with tyrosine kinase inhibitors, and to raise awareness on the management of sunitinib induced colitis.

16 May 2024 in Cancer Medicine
Verified
Journal Article
Open access
AUAnt Uzay
Ant Uzay
YGYasemin Gündoğdu
Yasemin Gündoğdu
BKBarış Koşan
Barış Koşan
TYTuğba Yetiş
Tuğba Yetiş
SKS. Sami Kartı
S. Sami Kartı
Introduction: Type of conditioning regimen impacts the outcome of patients who undergo allogeneic HSCT since graft versus host disease (GVHD), infections, regimen related toxicities (RRT) are important causes of post‐transplant mortality. Despite the RRT profile of busulfan, it is frequently used worldwide. Treosulfan has advantages in terms of dose of administration, lower incidence of sinusoidal obstruction syndrome and lower neurotoxicity. We retrospectively investigated outcomes of patients who underwent allogeneic HSCT with treosulfan or busulfan based conditioning regimens in our institution.Methods: Treosulfan was administered to 94 patients while 85 patients received busulfan. Our outcomes were RRT, chronic and acute GVHD, relapse related mortality (RRM), non‐relapse mortality, and fungal infection. The clinical follow up data, regarding the primary and secondary endpoints of our study, of the patients who received treosulfan or busulfan based conditioning regimens were statistically analyzed.Results: The median follow‐up was 14 months for the treosulfan group while it was 11 months for the busulfan group (p = 0.16). RRT was 11.7% and 7.1% for treosulfan and busulfan respectively. The incidence of extensive chronic GVHD was less frequent in the treosulfan group compared to the busulfan group (15.7% vs. 32.1%) (p < 0.001). The incidence of acute GVHD (Grade 3 or higher) was 32.2% in the treosulfan group while it was 31.6% in the busulfan group. The RRM was 17% in the treosulfan group while it was 34% in the busulfan group. The non‐relapse mortality was 35.5% and 29.4% in the treosulfan group and in the busulfan group respectively (p = 0.962).Conclusion: Treosulfan, with a lower RRM, lower chronic GVHD incidence and with a similar RRT profile appears to be a safe alternative to busulfan.

30 April 2021 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
ASAral Sürmeli
Aral Sürmeli
ÖBÖykü Beyaz
Öykü Beyaz
EKElif Sitre Koç
Elif Sitre Koç
YGYasemin Gündogdu
Yasemin Gündogdu
ÇÇÇaglar Çuhadaroglu
Çaglar Çuhadaroglu
SKSesin Kocagöz
Sesin Kocagöz
Objective: Information on characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients in Turkey is limited. We aimed to describe the characteristics and outcomes of patients hospitalised with COVID-19 and compare patients who required intensive care unit (ICU) admission with those who did not require it. Materials and Methods: This retrospective cross-sectional study was conducted in a tertiary care hospital in Istanbul. A total of 215 patients hospitalised with COVID-19 between 9 March 2020 and 30 April 2020 were included. Demographic, clinical, laboratory and radiological data on admission and outcomes were analysed. The main outcomes were COVID-19 ward or ICU hospitalisation, invasive mechanical ventilation requirement, discharge, or death. Presenting characteristics were compared between patients who required ICU admission with those who did not require it. Results: Among 215 patients, 64% were male, and the median age was 53. The most prevalent comorbidity was hypertension, followed by diabetes mellitus and coronary artery disease. The prevalence of comorbidities and the median age was higher in patients in ICU. The most common presenting symptom was fever (72%). C-reactive protein (CRP), lactate dehydrogenase (LDH), neutrophil and lymphocyte count, ferritin, and d-dimer levels were significantly different between ICU and non-ICU patients. However, in the final logistic model, among presenting symptoms, initial radiographs and laboratory tests, having dyspnea, high CRP and LDH were significantly associated with ICU admission. Conclusion: Of 215 hospitalised patients with COVID-19, 17% of patients required ICU admission, and the mortality rate was 4.4%. Older age, having coronary artery disease, high levels of CRP, LDH, and presenting with dyspnea were significantly associated with ICU admission. Keywords: Infections, Pneumonia, Critical Care

15 December 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
YBYeşim Beşli
Yeşim Beşli
SOSinem öktem okullu
Sinem öktem okullu
YGYasemin Gündoğdu
Yasemin Gündoğdu
ODOrhan Cem Deniz
Orhan Cem Deniz
Acute non-traumatic joint pain, swelling, and fever require prompt evaluation for a prosthetic joint infection, a serious bacterial complication affecting both large and small joints. Neisseria gonorrhoeae and Staphylococcus aureus are among the most common causes, typically involving a single joint. To the best of our knowledge, we report the first case of a prosthetic joint infection caused by Neisseria macacae, highlighting its relevance for differential diagnosis. Identification was achieved using MALDI-TOF and confirmed with next-generation sequencing. While N. gonorrhoeae and Neisseria meningitidis are well-recognized pathogens, other Neisseria species may cause opportunistic infections, underscoring the importance of comprehensive microbiological evaluation.